An in vitro system to model pulmonary epithelial barrier dysfunction mediated by immune effector cells

Area of Science:

• Immunology
• Cell Biology
• Pulmonary Medicine

Background:

• Pulmonary allograft rejection and inflammatory lung diseases involve immune-mediated damage to lung epithelial barrier function.
• Monitoring changes in lung permeability is crucial for understanding these conditions.
• Existing methods may lack the sensitivity or specificity to fully capture these dynamic changes.

Purpose of the Study:

• To develop and validate a novel in vitro assay for assessing epithelial barrier function.
• To monitor immune-mediated changes in lung permeability.
• To model epithelial damage relevant to pulmonary allograft rejection and inflammatory lung diseases.

Main Methods:

• Cultured primary lung epithelial cells from minipigs.
• Purified epithelial cells using differential detachment and confirmed with anti-cytokeratin antibody.
• Measured transmonolayer resistance across cell monolayers cultured on porous inserts.
• Assessed the impact of cytotoxic immune effector cells and unstimulated splenocytes on barrier integrity.

Main Results:

• Established stable epithelial monolayers with functional intercellular tight junctions, indicated by high transmonolayer resistance (mean 5487 +/- 2882 omega).
• Demonstrated that cytotoxic immune effector cells rapidly reduced transmonolayer resistance.
• Showed that unstimulated splenocytes did not significantly alter resistance, highlighting assay specificity.
• Confirmed the sensitivity of the transmonolayer resistance technique compared to standard isotopic cytotoxicity assays.

Conclusions:

• The developed assay accurately models immune-mediated epithelial permeability damage in vitro.
• This technique enables the study of lung barrier dysfunction caused by activated lymphoid cells and their products.
• The assay provides a sensitive tool for research into pulmonary allograft rejection and inflammatory lung diseases.